ProShare Advisors LLC Acquires 17,590 Shares of BioLife Solutions, Inc. $BLFS

ProShare Advisors LLC acquired a new position in shares of BioLife Solutions, Inc. (NASDAQ:BLFS) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 17,590 shares of the medical equipment provider’s stock, valued at approximately $683,000.

Other hedge funds also recently made changes to their positions in the company. Transmarket Holdings LP purchased a new stake in shares of BioLife Solutions in the third quarter valued at about $5,366,000. Yousif Capital Management LLC increased its stake in shares of BioLife Solutions by 4.9% during the third quarter. Yousif Capital Management LLC now owns 11,097 shares of the medical equipment provider’s stock worth $431,000 after acquiring an additional 520 shares during the period. Kings Path Partners LLC purchased a new position in BioLife Solutions during the third quarter worth about $644,000. Nisa Investment Advisors LLC raised its holdings in BioLife Solutions by 13.3% during the third quarter. Nisa Investment Advisors LLC now owns 2,209 shares of the medical equipment provider’s stock worth $86,000 after purchasing an additional 260 shares in the last quarter. Finally, Abel Hall LLC purchased a new position in BioLife Solutions during the third quarter worth about $224,000. Institutional investors and hedge funds own 93.24% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently commented on BLFS shares. Benchmark downgraded shares of BioLife Solutions from a “buy” rating to a “hold” rating in a research report on Monday, August 10th. Craig Hallum cut BioLife Solutions from a “buy” rating to a “hold” rating and set a $31.00 target price on the stock. in a research report on Wednesday, July 22nd. HC Wainwright downgraded BioLife Solutions from a “buy” rating to a “neutral” rating and cut their target price for the stock from $32.00 to $31.00 in a research note on Thursday, July 23rd. William Blair set a $31.00 price target on BioLife Solutions in a report on Thursday, July 23rd. Finally, TD Cowen downgraded BioLife Solutions from a “buy” rating to a “hold” rating and decreased their price target for the company from $33.00 to $31.00 in a research note on Wednesday, July 22nd. One analyst has rated the stock with a Buy rating and ten have issued a Hold rating to the stock. According to MarketBeat.com, BioLife Solutions has an average rating of “Hold” and a consensus price target of $31.38.

BioLife Solutions Stock Performance

Shares of BioLife Solutions stock opened at $38.61 on Monday. BioLife Solutions, Inc. has a 12-month low of $17.86 and a 12-month high of $39.76. The stock has a market cap of $1.89 billion, a PE ratio of 33.28 and a beta of 1.82. The company has a 50-day moving average of $37.68 and a two-hundred day moving average of $28.31.

BioLife Solutions (NASDAQ:BLFS) last posted its quarterly earnings results on Thursday, August 6th. The medical equipment provider reported $0.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.03 by $0.88. The company had revenue of $28.47 million during the quarter, compared to the consensus estimate of $27.80 million. BioLife Solutions had a net margin of 53.29% and a return on equity of 2.70%. On average, sell-side analysts forecast that BioLife Solutions, Inc. will post 0.03 EPS for the current fiscal year.

About BioLife Solutions

BioLife Solutions, Inc develops and supplies products and services used to preserve, process, store and transport biological materials. Its solutions support the development and manufacture of cell and gene therapies, including products designed to help maintain the viability and functionality of cells, tissues and other biologic materials throughout the bioprocessing workflow.

The company’s portfolio includes preservation media such as CryoStor and HypoThermosol, cell thawing and handling products, and related storage and shipping systems.